CPHI
China Pharma Holdings, Inc.
There isn't enough reported data to score CPHI yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CPHI Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Stable | |
| Weak |
CPHI's cash flow is currently stable, but its revenue, profitability and balance sheet are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CPHI PE Valuation
CPHI has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CPHI Forward outlook
There aren't enough analyst estimates for CPHI to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CPHI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.42 | +$1.08 |
| Q1 2026 | -$0.54 | +$1.70 |
| Q4 2025 | -$0.74 | +$1.96 |
| Q3 2022 | -$35.00 | +$10.00 |
| Q2 2022 | -$35.00 | +$10.00 |
| Q1 2022 | -$35.00 | $0.00 |
| Q4 2021 | -$35.00 | $0.00 |
| Q3 2021 | -$45.00 | +$190.00 |
CPHI has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CPHI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $948.3K | -7.5% |
| Q1 2026 | $983.5K | -13% |
| Q4 2025 | $1.2M | +8.1% |
| Q3 2025 | $756.2K | -31% |
| Q2 2025 | $1M | +11% |
| Q1 2025 | $1.1M | -17% |
| Q4 2024 | $1.1M | -47% |
| Q3 2024 | $1.1M | -39% |
CPHI's revenue has slid since its 2020 peak: $948,340 last quarter, down 7.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -151% | -87 points |
| Q1 2026 | -114% | -47 points |
| Q4 2025 | -98% | +7.6 points |
| Q3 2025 | -83% | +16 points |
| Q2 2025 | -64% | +87 points |
| Q1 2025 | -67% | +0.1 points |
| Q4 2024 | -105% | -50 points |
| Q3 2024 | -99% | -59 points |
CPHI's operating margin was −151% last quarter, down 87 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CPHI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CPHI on profitability, with a higher operating margin.
CPHI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2025 | -$237.6K | -$190.6K |
| Q2 2025 | $291.1K | +$363.9K |
| Q1 2025 | -$116.1K | +$469K |
| Q3 2024 | -$47K | -105% |
| Q2 2024 | -$72.7K | +$143.7K |
| Q1 2024 | -$585.2K | +$883.1K |
| Q4 2023 | -$22.3K | -104% |
| Q3 2023 | $1M | +$1M |
CPHI has the stronger cash trend. Its trailing FCF is up 110% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
CPHI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +58% | +14.9M shares |
| 1 year | +1142% | +37.3M shares |
| 3 years | +40409% | +40.4M shares |
| 5 years | +46392% | +40.4M shares |
| Available history | +46392% | +40.4M shares |
CPHI has 41M diluted shares, up 1142% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CPHI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CPHI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | 1,068.6x | High |
| Q1 2022 | 217.7x | High |
| Q4 2021 | 20.8x | High |
| Q1 2021 | 92.7x | High |
| Q4 2020 | 42.3x | High |
CPHI's net debt is more than 20 years of its operating earnings (EBITDA), up from more than 20 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CPHI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.4 | Neutral |
| Stochastic | 5.4 | Oversold |
CPHI's weekly RSI is 41 (neutral) and its Stochastic is 5 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CPHI PE vs Healthcare Sector
CPHI has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CPHI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.68 | 18% below |
| 20 week MA | $0.84 | 33% below |
| 50 week MA | $0.86 | 35% below |
| 100 week MA | $1.37 | 59% below |
| 200 week MA | $5.78 | 90% below |
CPHI is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CPHI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $121.5 | $223.8 | +84% |
| 2021 | $223.8 | $215.1 | -3.9% |
| 2022 | $215.1 | $58.3 | -73% |
| 2023 | $58.3 | $6.05 | -90% |
| 2024 | $6.05 | $2.10 | -65% |
| 2025 | $2.10 | $1.29 | -39% |
| 2026 YTD | $1.29 | $0.56 | -57% |
CPHI has finished five years in a row lower, and it's down 57% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over CPHI on returns for 2026, with the stronger performance.